Millendo Therapeutics (NASDAQ:MLND) released its quarterly earnings data on Monday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.07, Bloomberg Earnings reports.
MLND opened at $7.10 on Wednesday. The company’s fifty day moving average price is $10.46. The firm has a market cap of $100.93 million, a price-to-earnings ratio of -0.40 and a beta of 2.64. Millendo Therapeutics has a twelve month low of $6.77 and a twelve month high of $17.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.83 and a current ratio of 7.83.
Several research firms have recently issued reports on MLND. Citigroup began coverage on shares of Millendo Therapeutics in a research report on Monday, July 15th. They issued an “outperform” rating and a $26.00 price objective for the company. ValuEngine raised shares of Millendo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. CIBC began coverage on shares of Millendo Therapeutics in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $26.00 price objective for the company. Wedbush began coverage on shares of Millendo Therapeutics in a research report on Thursday, July 18th. They issued an “outperform” rating and a $24.00 price objective for the company. Finally, Zacks Investment Research raised shares of Millendo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Millendo Therapeutics presently has a consensus rating of “Buy” and an average target price of $24.25.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Recommended Story: What is a price target?
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.